Monoclonal Antibodies in Pregnancy of Patients with Systemic Lupus Erythematosus: Friend or Foe? A Case Report of a Patient with Multiple Pregnancies
Authors:
- Chiara OrlandiCOChiara Orlandi
- Angela TincaniATAngela Tincani
- Micaela FrediMFMicaela Fredi
- Laura AndreoliLALaura Andreoli
- Francesca CrisafulliFCFrancesca Crisafulli
- Liala MoschettiLMLiala Moschetti
- Cecilia NalliCNCecilia Nalli
- Maria Grazia LazzaroniMLMaria Grazia Lazzaroni
- Marco TagliettiMTMarco Taglietti
- Matteo FilippiniMFMatteo Filippini
- Sonia ZattiSZSonia Zatti
- Laura PicciauLPLaura Picciau
Open Access
- 8 April 2026
- journal article
- case report
- Published by MDPI AG in Antibodies
- Vol. 15 (2) , 32
Abstract
Systemic lupus erythematosus (SLE) is an autoimmune disease that predominantly affects women of childbearing age, and active disease during pregnancy is associated with increased maternal and fetal morbidity. Belimumab is an effective biologic therapy for active SLE; however, its use during pregnancy has long been limited by the scarcity of safety data. Recent evidence and updated international recommendations suggest that belimumab may be considered in selected cases when required to maintain maternal disease control. We report the case of a woman with SLE who experienced three consecutive pregnancies with live births between 2019 and 2024 while receiving belimumab, allowing an intra-individual comparison of different exposure strategies. During the first pregnancy, belimumab was discontinued at conception and was followed by a disease flare in late pregnancy and postpartum. In the second and third pregnancies, belimumab was continued until gestational week 20 following shared decision-making with the patient; nevertheless, disease flares occurred during the third trimester of both pregnancies. All pregnancies resulted in live births at term, with no congenital anomalies, placental insufficiency, or fetal growth restriction. One neonate from the third pregnancy developed early-onset neonatal sepsis and meningitis, which resolved completely after antibiotic treatment. All children are currently growing and developing normally. This case supports a risk-adapted approach to belimumab use during pregnancy. In selected women with SLE at high risk of disease reactivation, continuation of belimumab until mid-gestation may contribute to improved maternal disease control without evident adverse fetal outcomes.Keywords
This publication has 28 references indexed in Scilit:
- EULAR recommendations for the management of systemic lupus erythematosus with kidney involvement: 2025 updateAnnals of the Rheumatic Diseases, 2025
- EULAR recommendations for use of antirheumatic drugs in reproduction, pregnancy, and lactation: 2024 updateAnnals of the Rheumatic Diseases, 2025
- Neonatal Fc Receptor — Biology and TherapeuticsNew England Journal of Medicine, 2025
- Pregnancy outcome predictors in systemic lupus erythematosus: a systematic review and meta-analysisThe Lancet Rheumatology, 2024
- Immunological effects and safety of live rotavirus vaccination after antenatal exposure to immunomodulatory biologic agents: a prospective cohort study from the Canadian Immunization Research NetworkThe Lancet Child & Adolescent Health, 2023
- Belimumab use during pregnancy: Interim results of the belimumab pregnancy registryBirth Defects Research, 2022
- Pregnancy outcomes in patients treated with belimumab: Report from real-world experienceSeminars in Arthritis and Rheumatism, 2021
- Pregnancy and Systemic Lupus ErythematosusBest Practice & Research Clinical Obstetrics & Gynaecology, 2020
- Maternal immunisation: collaborating with mother natureThe Lancet Infectious Diseases, 2017
- Use of belimumab throughout pregnancy to treat active systemic lupus erythematosus—A case reportSeminars in Arthritis and Rheumatism, 2014